TAIO PHAR | Sales 2024 * | 325B 2.09B 167B | Sales 2025 * | 335B 2.15B 172B | Capitalization | 608B 3.9B 312B |
|---|---|---|---|---|---|
| Net income 2024 * | 14.4B 92.42M 7.38B | Net income 2025 * | 20.6B 132M 10.56B | EV / Sales 2024 * | 1.87 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.82 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 8,784 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 5.83% | 0 M€ | +2.73% | ||
| 0.79% | 0 M€ | +11.43% | ||
| 0.19% | 0 M€ | +3.57% |
Taisho Pharmaceutical Holdings Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture and sale of over-the-counter drugs, quasi-drugs, foods, medical supplies, hygiene products, and ethical drugs. The Company operates in two business segments. The Self-Medication segment is engaged in the research, development, manufacture and sale of over-the-counter drugs, quasi-drugs, foods, medical supplies, hygiene products. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of ethical drugs. The other business is engaged in the leasing and management of real estate, as well as hotel management business.
Sector
-
Calendar
12/05/2024
- Q4 2023 Earnings Release (Projected)
